Galectin Therapeutics Inc (GALT)
3.36
-0.02
(-0.59%)
USD |
NASDAQ |
Apr 18, 16:00
3.36
0.00 (0.00%)
After-Hours: 19:07
Galectin Therapeutics Enterprise Value: 257.54M for April 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 17, 2024 | 257.54M |
| April 16, 2024 | 258.78M |
| April 15, 2024 | 290.35M |
| April 12, 2024 | 294.06M |
| April 11, 2024 | 308.30M |
| April 10, 2024 | 284.78M |
| April 09, 2024 | 292.20M |
| April 08, 2024 | 279.82M |
| April 05, 2024 | 279.20M |
| April 04, 2024 | 234.02M |
| April 03, 2024 | 224.73M |
| April 02, 2024 | 203.68M |
| April 01, 2024 | 199.35M |
| March 28, 2024 | 196.25M |
| March 27, 2024 | 197.49M |
| March 26, 2024 | 195.02M |
| March 25, 2024 | 192.54M |
| March 22, 2024 | 199.35M |
| March 21, 2024 | 199.35M |
| March 20, 2024 | 184.49M |
| March 19, 2024 | 178.30M |
| March 18, 2024 | 180.78M |
| March 15, 2024 | 175.83M |
| March 14, 2024 | 170.87M |
| March 13, 2024 | 170.87M |
| Date | Value |
|---|---|
| March 12, 2024 | 170.25M |
| March 11, 2024 | 172.73M |
| March 08, 2024 | 174.59M |
| March 07, 2024 | 177.68M |
| March 06, 2024 | 177.06M |
| March 05, 2024 | 175.83M |
| March 04, 2024 | 171.49M |
| March 01, 2024 | 167.78M |
| February 29, 2024 | 169.33M |
| February 28, 2024 | 165.21M |
| February 27, 2024 | 163.35M |
| February 26, 2024 | 164.59M |
| February 23, 2024 | 164.59M |
| February 22, 2024 | 158.40M |
| February 21, 2024 | 163.35M |
| February 20, 2024 | 163.35M |
| February 16, 2024 | 155.93M |
| February 15, 2024 | 156.55M |
| February 14, 2024 | 155.31M |
| February 13, 2024 | 152.84M |
| February 12, 2024 | 150.98M |
| February 09, 2024 | 152.84M |
| February 08, 2024 | 149.12M |
| February 07, 2024 | 147.27M |
| February 06, 2024 | 152.84M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
40.90M
Minimum
Mar 18 2020
308.30M
Maximum
Apr 11 2024
136.06M
Average
127.72M
Median
Enterprise Value Benchmarks
| Madrigal Pharmaceuticals Inc | 4.025B |
| Viking Therapeutics Inc | 6.324B |
| 89bio Inc | 304.27M |
| Terns Pharmaceuticals Inc | 30.40M |
| Enanta Pharmaceuticals Inc | -40.97M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.997M |
| Total Expenses (Quarterly) | 9.561M |
| EPS Diluted (Quarterly) | -0.16 |
| Earnings Yield | -22.02% |